logo
Bunnings keeps competitors off its turf, but smaller players aren't so lucky

Bunnings keeps competitors off its turf, but smaller players aren't so lucky

When Bunnings announced plans to build a store right next to David Woodman's Mitre 10, he had few options to stop the hardware giant's expansion.
"They really want to put us out of business … I can only imagine that's their plan," David says.
But when a rival wants to move onto Bunnings's turf, that's a different story.
Emails seen by Four Corners show Bunnings has repeatedly used its size and market power to block competitors from setting up in retail precincts where it already has a store.
Such restrictive lease agreements are prohibited in the supermarket sector. But Bunnings is not subject to the same competition rules as Coles and Woolworths, despite rivals believing it has more market power than the pair combined.
Documents show a specialty tools retailer was looking to open a store in a homemaker centre on the NSW Central Coast last year, only to be told by the leasing agent: "Bunnings have exclusivity in the centre for tools."
It was the same story in 2021 on the Gold Coast and again in Melbourne.
"Bunnings have put a restriction clause on the development for all tool operators … not happy … I tried to get around it, however, it's in their contracts," the tool shop was told by another retailer who was looking at the Melbourne site.
Bunnings, which has 310 warehouses across the country, says such agreements are only used on "select occasions" to protect its investment and that these usually only last 10 years.
Such agreements were phased out in the supermarket sector from 2010 because the regulator, the Australian Competition and Consumer Commission (ACCC), saw them as a major impediment to competition.
This followed Coles and Woolworths agreeing to an enforceable undertaking with the ACCC.
Professor Clinton Free from Sydney University Business School says Bunnings is not subject to the same scrutiny as Coles or Woolworths.
"There's a number of interesting angles to the Bunnings story. It's an enormous success financially, but it also starts to raise big questions about market power," he says.
This general lack of scrutiny, despite its dominant market position, has allowed Bunnings to continue expanding with little pushback from the ACCC.
David Woodman has experienced this firsthand.
In 2019, Bunnings purchased the vacant block next to his Mitre 10 store in Jimboomba, south of Brisbane. Plans have been approved for a warehouse eight times larger than David's shop.
David, whose family has been in the hardware business for 90 years, is not optimistic about the prospects for his store.
"We'd expect to lose sales to the point where business will ultimately become unprofitable … we can't sustain that, so we'd probably end up shutting the store," he says.
He believes Bunnings chose the site to put him out of business.
"They know from other sites that that's what happens," he says.
Bunnings denies this, saying new store openings are about "enhancing", not eliminating, competition.
It says it engaged with the ACCC on the Jimboomba store, which it anticipates will open next year.
The ACCC said it could not comment.
But unlike Bunnings, David will find it difficult to block the hardware giant from setting up next door.
In a last-ditch effort, he has briefed lawyers in the hope of taking Bunnings to court for "misusing its market power".
He notes there are already three Bunnings stores within a 30-kilometre radius of his store and more than a dozen in greater Brisbane.
His is not the only local store that could be impacted.
Within a few blocks, there are businesses selling plumbing and landscaping supplies, mowers, water pumps, chainsaws, pool supplies and blinds. Some say the hardware giant's arrival could benefit their business, while some are deeply concerned.
Bunnings said in a statement its new store would bring more choice and competition and provide local jobs.
The creeping expansion of Bunnings is set to come under greater scrutiny when new competition laws come into effect next year.
These are expected to give the ACCC greater power to review purchases of existing shops, land or new lease agreements to determine if they lessen competition.
Treasurer Jim Chalmers is hedging his bets on whether Bunnings should be subject to a code of conduct similar to that imposed on the supermarkets.
"I'm aware that people have raised concerns about Bunnings," he says.
"Our primary focus is supermarkets, but we've given the ACCC the resources that they need and the ability to recommend to us a broader focus, if that's warranted."
The code of conduct is designed to help level the playing field between Bunnings and suppliers like George and Katherine Mingin.
For eight years, their regional Queensland business supplied live composting worms to Bunnings.
"At first it was great. It was fantastic," George says.
In the early years, the couple felt they had a solid partnership with Bunnings and had opportunities to grow their business. At their peak, their sales to Bunnings reached $1.3 million annually.
COVID hit, and like many businesses, the Mingins' costs rose sharply, eroding their margins and pushing them into $150,000 of debt. They were losing money on every packet of worms sold to Bunnings.
"Little by little they started applying more pressure on their suppliers, certainly on us, and the expectations started to grow," Katherine says.
The couple had no choice but to ask for a price increase.
"We just instinctively knew that asking for a price increase, however big or small, was not going to go well," says Katherine.
After months of being strung along, Bunnings eventually told the couple it was putting their contract out to tender. They say they were told Bunnings didn't want to sacrifice its profit margins — margins that were already very healthy.
The Mingins were selling a pack of 1,000 worms to Bunnings for $29.94, which was then sold in-store for $49.90 — a 66 per cent mark-up.
But this does not capture all the profits flowing to Bunnings.
Like many other suppliers, they had to pay money back to Bunnings, in the form of rebates based on their sales volumes.
During their time with Bunnings, documents seen by Four Corners show the Mingins paid a volume rebate of 7 per cent, a 15 per cent rebate for sales into new stores, and even a rebate to cover errors made in supplying orders into Bunnings.
Suppliers can also be charged for marketing or if their stock is discounted.
"It was just plain highway robbery," George says.
In the end, the couple lost the tender and more than three quarters of their business.
After eight years of supplying to Bunnings, they had little to show for it and were given just one week's notice to finish up.
And then Bunnings sent them a final bill for $5,000 in rebates.
Bunnings told Four Corners it does not comment on specific supplier agreements, but conducts business with "integrity, honesty and respect".
"We are committed to dealing with our suppliers fairly and ethically," it says.
Bunnings's market share is highly disputed.
It says it only accounts for 17 per cent, as it competes across several sectors, against a range of stores like Amazon, Coles, Myer, Spotlight and Petbarn.
Market research firm IBISWorld says Bunnings's parent company Wesfarmers has a 33 per cent share of the retail hardware sector, noting it is "far and away the leading player in the hardware retailing space". Some competitors claim the figure is much higher.
Bunnings was not always so dominant. While it began life as a WA timber company prior to federation, it only opened its first hardware warehouse in 1994. Back then, Mitre 10 was cited in news reports as being the dominant player with around 10 per cent market share.
Since then, Bunnings has expanded aggressively.
In 1993, it took over McEwans hardware, then in 2001 it moved on BBC Hardware, also trading as Hardware House, giving it a national footprint and allowing it to expand into New Zealand.
As the new millennium began, Bunnings had $1.4 billion in sales across 47 stores.
Today, its revenue is 13 times that across a massive empire called the Bunnings Group.
As well as 310 warehouses in Australia, stores in New Zealand, and an arm that makes timber trusses, it has specialist tile and tool chains, acquired with no objection from the ACCC.
Clinton Free says Bunnings deserves far more scrutiny given its size and market power.
"Attention needs to go into a category which is very large, which affects lots of consumers, affects lots of suppliers," he says.
"They really should be subject to the same sort of scrutiny and regulation as our big retailers."
David Woodman says if stores like his go, it is shoppers who will miss out — on choice and service.
"Hardware is heading exactly the same direction as the supermarkets. Only worse because they've at least got two bloody dominant players," he says.
"I am concerned that if Bunnings continues with its current conduct, many Australians will have no choice but to buy their hardware from Bunnings and nowhere else."
Watch Four Corners's full investigation, Hammered: Inside the Bunnings Machine on ABC iview.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

‘Why are you shaming me?': 30-year-old calls out stigma around ChatGPT
‘Why are you shaming me?': 30-year-old calls out stigma around ChatGPT

News.com.au

time26 minutes ago

  • News.com.au

‘Why are you shaming me?': 30-year-old calls out stigma around ChatGPT

A young Aussie woman has revealed she was rejected from a job because she used ChatGPT during the recruitment process – unearthing a controversial new workplace trend. Alexandra Frisby-Smith, 30, works as a virtual assistant. She recently applied for a role that would pay $80 an hour for five hours a week on an ongoing basis, resulting in an extra $20,000 a year. Ms Frisby-Smith explained to that she was going through the process which involved an interview, a questionnaire and a trial task. She was then given a list of tasks her potential employer needs to complete daily and asked to streamline them. 'I was brainstorming and thinking, 'Can I do it this way?' Or that way, basically bending and stretching and working out what platforms would work best,' she said. 'Once I worked out an overview, I popped that into ChatGPT and it created a cohesive and beautiful way of representing my thoughts.' Ms Frisby-Smith explained that since she was given 30 minutes to complete the task she figured using the AI tool was smart. 'The most efficient way was to brainstorm everything and then put it into ChatGPT, and that can make it cohesive and easy to digest,' she argued. After completing the task, she received an email from her potential employer explaining that she hadn't been hired because of her 'heavy use of ChatGPT,' which Ms Frisby-Smith found confusing. 'I'm not trying to hide the fact that I use it. Everyone has their different views, and I can see why people dislike it because it takes the humanness out of writing, which I think is what she was concerned about,' she said. At the end of the day, Ms Frisby-Smith ultimately thinks ChatGPT is simply a tool that makes her 'more efficient', so it is ultimately helpful. The virtual assistant said once she posted about her experience on TikTok she was surprised to learn how many people were 'afraid' of ChatGPT. 'They are afraid because it is new and it is different but it can make us more efficient but people are also feeling threatened,' she said. 'It is like having an assistant, like a real-life person you're working with and collaborating with.' Ms Frisby-Smith ultimately stands by her use of the AI tool and doesn't understand why there's a stigma around it. 'Why are you shaming me? When are we going to stop shaming people who use it?' she asked. The 30-year-old might have embraced the online tool, but others on social media are far wearier and don't see using the program as acceptable. 'When are we going to start shaming people for being too damn lazy to do the bare minimum?' one asked. 'Girl, come on,' another said. 'I use it,' one admitted. 'Nothing wrong with using it, but it's the lack of attention to detail that would've been the reason,' someone else noted. 'I'm struggling to take this seriously,' another chimed in. 'Nah, I think being able to write correspondence yourself is an important communication skill,' one argued. 'When are people going to realise that employers need to know your capabilities and not AI's capabilities?' someone asked. 'Don't get me wrong, ChatGPT is super useful, but something you're submitting should always be in your own words,' another recommended. Recruitment expert Roxanne Calder told that ChatGPT has already become the norm in the job interview process. One big thing she's noticing now is people sending through resumes using the AI chatbot and not bothering to add their own flair. 'Resumes get sent through in third person now,' she said. Ms Calder is realistic about the new technology, saying there's no point ignoring it, otherwise you'll get left behind. However she does think it needs to be used wisely. 'These tools are really great, and everyone should get across them and work out how to integrate, but it is really obvious when someone uses it and doesn't add their own words,' she said. Ms Calder said Chat GPT is fine if it is treated like a tool but it shouldn't be relied on to do your work for you. 'If you are lazy and don't integrate your thoughts, then the work isn't yours. If someone presents a piece of work to you and you ask them questions about it and they can't answer them it is undeniable you've used ChatGPT,' she said. 'It should be used as a tool only.' If you're making the chatbot app do all the work for you, then in Ms Calder's eyes, you've 'lost credibility'. And of course, that is going to hold you back from securing jobs.

Health Check: Mayne Pharma shareholders back $600m ‘phantom' takeover offer
Health Check: Mayne Pharma shareholders back $600m ‘phantom' takeover offer

News.com.au

time36 minutes ago

  • News.com.au

Health Check: Mayne Pharma shareholders back $600m ‘phantom' takeover offer

Mayne investors today strongly endorsed Cosette's non-existent takeover offer Audeara's improving sales are loud and clear We ferret around for all the latest clinical trial news Mayne Pharma (ASX:MYX) shareholders have overwhelmingly approved the company's $600 million takeover scheme of arrangement, even though suitor Cosette has terminated the deal. At the Melbourne meeting, the company reported 699 proxy votes in favour of 98.57%, compared with four 'nays' accounting for 0.95%. Open proxies accounted for a further 0.47% or so. The deal is a phantom one, in the sense that Cosette pulled out on the grounds that adverse material events had occurred. Such a withdrawal is allowable under the scheme implementation deed (SID). In a cross claim, Cosette alleges Mayne engaged in misleading or deceptive conduct. Mayne disputes these allegations and says the SID – now glowingly endorsed by investors – remains valid. The company has filed NSW Supreme Court proceedings to seek such a ruling. Chairman Frank Condella told holders the SID was subject to a favorable court adjudication, 'in the absence of any other agreement being able to be reached with Cosette in relation to the dispute.' He warned that if Mayne's legal quest fails, the company may be subject to 'financial detriment, including damages claims and/or costs orders and the payment of a break fee to Cosette ." That said, Mayne directors believe that it's in the shareholders' best interest to pursue litigation. Hear! Hear! Audeara in bullish trading update The maker of own-brand and white label devices to assist hearing, Audeara (ASX:AUA) says it is poised for a record year on the back of sales orders from two key clients. The company reported unaudited revenue for the year to June (eleven months) of $3.64 million, up 14% on the previous year and 25% higher than in the 2022-23 year. Audeara's fortunes have been underpinned by the launch of Taiwan hearing device leader Clinico's co-branded sound buds, which imbed Audeara's 'secret sauce' tech. This tie up resulted in an initial $570,000 order. The company also received a follow-up order of $917,000 from 400-year-old musical instrument maker Avedis Zildjian. Audeara also grew Australian wholesale sales by 16%, to $1.67 million. Management expects additional growth in coming weeks, including sales to wholesalers, retailers and resellers. We're 'earing different things about Cochlear Still on hearing devices, broking analysts have offered different takes on Cochlear's (ASX:COH) prospects after the company last Thursday downgraded full-year earnings expectations by 2-5%. And that's okay – it's a democracy after all. The company said its moderated outlook resulted from slowing growth for both cochlear implants and sound processors in its developed markets. Investors ponder to what degree Cochlear's new off-the-ear (OTE) Kanso 3 sound processor – and the next-gen implant Nucleus Nexa – will rev up sales. UBS has upped its call on the stock from neutral to a buy, with a new price target of $325 compared with $285 previously. The company believes Cochlear's new implants can boost its compound annual revenue growth by 10% over the next three year. Over this period, the firm expects Nucleus Nexa to increase Cochlear's global implant share by 3%, to 63%. Cochlear this month is launching the device in Europe and the Asia Pacific. Maintaining a 'hold', Morgans lowers its 'target price' from $286.24 to $281.36. 'While new systems tend to precede re-rates, we remain cautious,' the firm says. Morgans notes Nucleus Nexa 'appears more about refining the user experience as opposed to offering technological advancements as seen with prior implant iterations.' Sounds like the Iphone phenomenon, in that the 'wow factor' is dulled with every new release. Argenica pursues brain damage study Today's clinical trial updates come courtesy of rats, mice and ferrets and we thank these rodents and weasels for their sacrifice. In the case of Argenica Therapeutics (ASX:AGN), the brain and neurogenerative injuries specialist will forge head with a trial of its drug candidate ARG-007. This is for the hard-to-treat traumatic brain injury (TBI). This go-ahead follows a second preclinical study in a large cohort ferret. This showed ARG-007 resulted in 'significant long-lasting reduction in brain cell damage and inflammation following injury.' This 14-day study extended an initial three-day pilot effort. Aregenica says the ferret model 'closely resembles the gross anatomy of the human brain'. Combined with previous rat studies and the pilot ferret trial, this provides a 'robust preclinical data package'. TBI affects 69 million people globally annually, with no approved therapies. The University of Adelaide carried out the study, partly funded by a federal grant. The results should soothe investor disappointment over last week's setback, when the FDA placed a 'clinical hold' on Argenica's request to carry out a US ischaemic stroke trial. However, the company says its local phase II trial, now at dosing stage, is unaffected. Inoviq's (Exo) Ace trial news Inoviq (ASX:IIQ) reports that in vitro lab work has shown that one of its drug candidates killed 88% of aggressive triple negative breast cancer and lung cancer cells. The treatment deploys exosomes: tiny particles that deliver targeted therapies. The story gets complex because Inoviq uses engineered immune cell particles called CAR-NK-EVs, overlaid with its special process called Exo-Ace. The short explanation is the efforts could lead to an 'off the shelf' therapy that is faster, safer and more effective than traditional cell therapies (such as burgeoning CAR-T treatments that involve tricking up the T cells). Inoviq now will test the treatment in mice. It's very early days, but Inoviq shares this morning surged as much as 21%. Lumos enrolls its 500th patient Meanwhile, Lumos Diagnostics (ASX:LDX) has enrolled its 500 th patient in a study to clear its Febridx assay for US sale. A point-of-care test, Febridx rapidly distinguishes between bacterial and viral infections. The tricky bit is enrolling enough bacteria-positive patients and to date the company has corralled 78 of the requisite 120. By reaching 500 patients, Lumos has pocketed a US$298,457 milestone payment from its partner, the Biomedical Advanced Research and Development Authority (BARDA). BARDA hands over another US$746,143 when the trial enrols the last patients. Lumos doesn't specific a number, but expects the process to complete by the end of 2025. Lumos is seeking so-called CLIA (Clinical Laboratory Improvements Amendment) waiver. This enables simple tests to be used by less trained staff such as nurses and receptionists.

Business listed for sale complete with a camel called Sandy
Business listed for sale complete with a camel called Sandy

News.com.au

timean hour ago

  • News.com.au

Business listed for sale complete with a camel called Sandy

A unique business opportunity is for sale, and it comes complete with a camel called Sandy. Operating at EcoPark Fishing Park & Farm Stay, the 3.11ha site is located at Luscombe, which is located between Brisbane and the Gold Coast. Listed with Ray White Shore Group, 2 Hall St is zoned Commercial and classified as a Special Tourist Attraction. It boasts 'beautifully landscaped grounds featuring fishing ponds, open picnic areas, native wildlife, and engaging family-friendly activities'. At the entrance is a retail gift shop and fully operational kitchen, servicing visitors and guests throughout the week. An onsite property also provides a steady income stream. The business website describes it as a fishing park and farm stay. There are two accommodations types - the EcoPark Lodge and overnight camping for one group only. Exclusive overnight camping starts at $499 for four people, with an additional $75 per person, right up to $1500 for 20 people, and $75 per person after that. EcoPark Lodge is a self-contained house that sleeps up to 18 people. Activities include fishing, with all gear supplied, a 36-hole mini golf course, animal and bird feeding, a jumping castle, paddleboats. waterbikes, large boardgames, swings and slides, table tennis and football. There is also pedal go karts, 4WD buggy rides and tours. The catch and release fishing involves try to land one of the thousands of fish within the ponds, including Barcoo Grunter, Sooty Grunter, Silver Perch, Eel-tailed catfish, Australian Bass, Golden Perch (or Yellow Belly) and Murray Cod. 'Our catch and release policy ensure that there are plenty of fish for all to enjoy catching,' the website says. ATO's dragnet: Millions of side hustles face shock tax bill And as for the other animals, these include Sandy the Camel, rabbits Miss Poppins and Lady Blue, a number of macaws, deer, and Dorothy the Pig. The website also says that a shark and ray encounter is 'coming soon'. There is also peacocks, donkeys, sheep, goats, guinea pigs, ducks, turkeys and baby chicks.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store